Tradestie Institutional Equity Comparison Engine

LCTX vs XERS โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-19 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

XERS Overall Edge

XERS Captures Institutional Edge (3โ€“1 Pillars ยท 4โ€“6 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Xeris Biopharma Holdings, Inc. Common Stock (XERS) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while LCTX counters with relative strength in Valuation. Fundamentally, LCTX trades at 30.7x Forward P/E with -280.3% operating margin (-61.0% YoY revenue) versus XERS at 62.3x Forward P/E and 12.7% operating margin (+44.2% YoY). In options structure, LCTX sits in BREAKDOWN (100th %ile IV; Dealer Gamma Walls on Pro) against XERS sits in SURGE (12th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner LCTX
LCTX 30.7x vs XERS 62.3x Fwd P/E
Growth & Margin Winner XERS
Op Margin -280.3% vs 12.7% ยท YoY -61.0% vs +44.2%
Momentum & Technical Winner XERS
1Y -53.7% vs +134.8% ยท 52W Pos 4% vs 94%
Options & Structure Winner XERS
BREAKDOWN (100th %ile IV) vs SURGE (12th %ile IV)
LCTX NYSE American
Lineage Cell Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$0.82
-2.21% 1D
Market Cap $212.1M
1M Return -13.82%
1Y Return -53.67%
Forward P/E 30.7x
Unified AI Score
58.9 / 100 HOLD
Tech 65.0 Fund 54.0 Flow 65.0 Mom 45.0
XERS NASDAQ
Xeris Biopharma Holdings, Inc. Common Stock
Pharmaceutical Preparations
$16.62
-2.18% 1D
Market Cap $3.1B
1M Return +54.1%
1Y Return +134.75%
Forward P/E 62.3x
Unified AI Score
36.5 / 100 SELL
Tech 50.0 Fund 32.0 Flow 71.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: LCTX -53.67% XERS +134.75% Spread: +188.42 pp (XERS Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period LCTX Revenue XERS Revenue LCTX Op. Margin XERS Op. Margin Margin Edge
FY2018 $0M N/A -837.9% N/A LCTX
FY2019 $0M N/A -1106.0% N/A LCTX
FY2020 $0M $20M -1448.4% -414.5% XERS
FY2021 $0M $50M -1133.6% -232.2% XERS
FY2022 $10M $110M -153.2% -74.3% XERS
FY2023 $10M $160M -276.5% -26.8% XERS
FY2024 $10M $200M -226.1% -16.6% XERS
FY2025 $10M $290M -251.6% 8.5% XERS

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: LCTX (6) vs XERS (4)
Institutional Metric LCTX XERS Criterion Row Winner
Market Capitalization Scale $212.1M $3.1B Larger Scale XERS
Trailing P/E Ratio Valuation 30.7x 86.2x Lower Multiple LCTX
Forward P/E Ratio Valuation 30.7x 62.3x Lower Multiple LCTX
Revenue Growth (YoY) Growth -61.0% +44.2% Higher Growth XERS
Operating Margin (TTM) Profitability -280.3% 12.7% Higher Margin XERS
Net Profit Margin Profitability 16.2% -1.8% Higher Margin LCTX
Return on Equity (ROE) Capital Efficiency 4.3% -27.1% Higher ROE LCTX
52-Week Range Position Momentum 4% ($1โ€“$2) 94% ($5โ€“$17) Stronger Trend XERS
Beta / 30D Volatility Risk Regime 1.36ฮฒ ยท 79% Vol -0.03ฮฒ ยท 104% Vol Lower Realized Risk LCTX
Unified Institutional Score Composite Signal 58.9 / 100 (HOLD) 36.5 / 100 (SELL) Higher Composite LCTX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full LCTX vs XERS Buy Guide
LCTX BREAKDOWN
6d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 100th %ile
IV Regime Extreme (>80th %ile)
Live LCTX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
XERS SURGE
5d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 12th %ile
IV Regime Compressed (<25th %ile)
Live XERS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither LCTX nor XERS registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.